Please login to the form below

Not currently logged in
Email:
Password:

Mylan deal with Roche clears path to biosimilar Herceptin launch

Covers global markets with the exception of Japan, Brazil and Mexico

Mylan building

After months of wrangling in the courts, Mylan and Roche have agreed a licensing deal that should allow a biosimilar version of breast cancer drug Herceptin to reach the market.

Mylan said the settlement will "provide a clear pathway" for sales of its biosimilar copy of HER2-targeting Herceptin (trastuzumab) – which had revenues of  $6.73bn last year – in all markets around the world except Japan, Brazil and Mexico.

The FDA has already accepted Mylan's Biologics Licensing Application (BLA) for its biosimilar trastuzumab and a verdict is due from the agency by September 3, so the company "anticipates potentially being the first company to launch a biosimilar to Herceptin in the US". The biosimilar has not yet been filed in Europe.

Mylan's biosimilar development partner Biocon has co-marketing rights in some markets outside North America, Europe, Japan and Oceania, and the two companies have already launched their copycat Herceptin in 14 emerging markets, including India.

Roche has always asserted that its patent estate for Herceptin was not due to expire in the US until 2019, but the settlement will save both companies the not-inconsiderable expense of fighting their patent infringement battle, although there are other biosimilar Herceptin developers waiting in the wings, including Amgen/Allergan, Pfizer, and Samsung Bioepsis. Financial details of the Mylan settlement have not been disclosed.

The emergence of biosimilars is expected to be challenging for Roche, which derives so much of its revenues from antibody drugs that have now started to lose patent protection. Aside from Herceptin, and biosimilars of Roche's Avastin (bevacizumab) and Rituxan/MabThera (rituximab) are also starting to reach the market.

Despite the competition, EvaluatePharma has suggested that Roche's blockbuster products will still be bringing in good revenues for the foreseeable future, as biosimilars do not tend to cause the steep declines on brands as traditional generics.

A recent forecast suggested Herceptin will be particularly resilient, still near-$4bn product in 2022, helped by combination use with Roche's newer HER2 drug Perjeta (pertuzumab) which grew 26% to more than $1.8bn last year.

Article by
Phil Taylor

14th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

the_other_side_of_rheumation_arthritis_thumb.jpg
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”...
The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....
Why pharma content marketing campaigns should be agile
Agile pharma content marketing is simply about responding to customer needs, rather than your own whims....

Infographics